<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Vorinostat (suberoylanilide <z:chebi fb="0" ids="24650">hydroxamic acid</z:chebi>, SAHA, Zolinza) is a <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor with clinical activity in cutaneous T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>A phase I trial of oral vorinostat was conducted in Japanese patients with malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Vorinostat 100 or 200 mg was administered twice daily for 14 consecutive days followed by a 1-week rest interval </plain></SENT>
<SENT sid="3" pm="."><plain>Of 10 patients enrolled, four had follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), two mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), two diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CTCL</z:e> (median age, 60 years; median number of prior regimens, 3) </plain></SENT>
<SENT sid="4" pm="."><plain>Vorinostat was well tolerated up to 200 mg with only one of six patients developing a dose-limiting toxicity (DLT; Grade 3 <z:hpo ids='HP_0002039'>anorexia</z:hpo>/<z:hpo ids='HP_0002900'>hypokalemia</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>Common Grade 3 events were reversible <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (30%), <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, and <z:hpo ids='HP_0002918'>hypermagnesemia</z:hpo> (20% each) </plain></SENT>
<SENT sid="6" pm="."><plain>The median number of treatment cycles was five (range, 1-36); two patients were continuing treatment </plain></SENT>
<SENT sid="7" pm="."><plain>The overall response rate was 40%, with two complete responses/unconfirmed (CRu) and one partial response among FL patients and one CRu among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>One FL patient maintained CRu for 18.0 months </plain></SENT>
<SENT sid="9" pm="."><plain>The median time to achieve CRu among the three patients was 8 months </plain></SENT>
<SENT sid="10" pm="."><plain>These data suggest that further investigations of vorinostat in non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, focusing on FL and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, are warranted </plain></SENT>
</text></document>